Cite
The safety and acceptability of twice‐daily deferiprone for transfusional iron overload: A multicentre, open‐label, phase 2 study.
MLA
Badawy, Sherif M., et al. “The Safety and Acceptability of Twice‐daily Deferiprone for Transfusional Iron Overload: A Multicentre, Open‐label, Phase 2 Study.” British Journal of Haematology, vol. 197, no. 1, Apr. 2022, pp. e12–15. EBSCOhost, https://doi.org/10.1111/bjh.17999.
APA
Badawy, S. M., Kattamis, A., Ezzat, H., Deschamps, B., Sicard, E., Fradette, C., Zhao, F., Tricta, F., Chung Tsang, Y., Sheth, S., & Piga, A. (2022). The safety and acceptability of twice‐daily deferiprone for transfusional iron overload: A multicentre, open‐label, phase 2 study. British Journal of Haematology, 197(1), e12–e15. https://doi.org/10.1111/bjh.17999
Chicago
Badawy, Sherif M., Antonis Kattamis, Hatoon Ezzat, Benoît Deschamps, Eric Sicard, Caroline Fradette, Feng Zhao, et al. 2022. “The Safety and Acceptability of Twice‐daily Deferiprone for Transfusional Iron Overload: A Multicentre, Open‐label, Phase 2 Study.” British Journal of Haematology 197 (1): e12–15. doi:10.1111/bjh.17999.